Liraglutide biosimilar (Zhuhai United)

利拉鲁肽生物类似药（珠海联邦）

Report date: 2025/03/21 16:16:31

Base Information

Drug NameLiraglutide biosimilar (Zhuhai United)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant polypeptideBiologics > Biosimilar
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryMainland China
Original Approved Date2025/03/18
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesZhuhai United Laboratories Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesZhuhai United Laboratories Co Ltd
Inactive CompaniesZhuhai Federation Biomedicine Co Ltd
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A